Limits...
The DRD3 Ser9Gly Polymorphism Predicted Metabolic Change in Drug-Naive Patients With Bipolar II Disorder

View Article: PubMed Central - PubMed

ABSTRACT

Patients with bipolar II disorder (BDII) have a higher prevalence rate of metabolic disturbance. Whether BDII itself, in addition to its current standard treatment, is a risk factor for metabolic syndrome warrants additional study. The dopamine receptor D3 (DRD3) gene, one of the candidate genes for BDII, is also involved in the dopaminergic system. We investigated whether it is related to changes in the metabolic indices of patients with BDII given 12 weeks of standard treatment.

Patients with a first diagnosis of BDII (n = 117) were recruited. Metabolic profiles (cholesterol, triglycerides, fasting serum glucose, body mass index) were measured at baseline and at 2, 8, and 12 weeks. The genotype of the DRD3 Ser9Gly polymorphism (rs6280) was determined. Multiple linear regressions with generalized estimating equation methods were used.

Seventy-six (65.0%) patients completed the 12-week intervention. Significant differences in triglyceride change were associated with the DRD3 Ser9Gly genotype (P = 0.03). Patients with the Ser/Ser genotype had significantly smaller triglyceride increases and a lower risk of developing metabolic syndrome than did those with the Ser/Gly+Gly/Gly genotype. However, the associations between the DRD3 Ser9Gly polymorphism with changes in triglyceride level become nonsignificant after correcting for multiple comparisons.

We conclude that the DRD3 Ser9Gly polymorphism is nominally associated with changes in triglycerides and metabolic syndrome after 12 weeks of standard BDII treatment.

No MeSH data available.


Related in: MedlinePlus

Changes in the triglyceride level of patients with different genotypes of the DRD3 Ser9Gly polymorphism after 12 weeks of standard treatment for bipolar II disorder. (The error bars represent the standard error of the mean).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4998429&req=5

Figure 1: Changes in the triglyceride level of patients with different genotypes of the DRD3 Ser9Gly polymorphism after 12 weeks of standard treatment for bipolar II disorder. (The error bars represent the standard error of the mean).

Mentions: A multiple linear regression analysis of the association between the DRD3 Ser9Gly polymorphism and changes in the metabolic parameter scores before and after the 12 weeks of treatment showed that the DRD3 Ser9Gly polymorphism was significantly (P = 0.03) associated with the changes in triglyceride levels (Table 2; Figure 1). Patients with the Ser/Ser genotype had a significantly smaller increase in triglycerides than did patients with the Ser/Gly + Gly/Gly genotype. However, the DRD3 Ser9Gly polymorphism was not associated with changes in other metabolic parameters (Table 2). After correcting for multiple comparisons, the associations between the DRD3 Ser9Gly polymorphism with changes in triglyceride levels become nonsignificant.


The DRD3 Ser9Gly Polymorphism Predicted Metabolic Change in Drug-Naive Patients With Bipolar II Disorder
Changes in the triglyceride level of patients with different genotypes of the DRD3 Ser9Gly polymorphism after 12 weeks of standard treatment for bipolar II disorder. (The error bars represent the standard error of the mean).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4998429&req=5

Figure 1: Changes in the triglyceride level of patients with different genotypes of the DRD3 Ser9Gly polymorphism after 12 weeks of standard treatment for bipolar II disorder. (The error bars represent the standard error of the mean).
Mentions: A multiple linear regression analysis of the association between the DRD3 Ser9Gly polymorphism and changes in the metabolic parameter scores before and after the 12 weeks of treatment showed that the DRD3 Ser9Gly polymorphism was significantly (P = 0.03) associated with the changes in triglyceride levels (Table 2; Figure 1). Patients with the Ser/Ser genotype had a significantly smaller increase in triglycerides than did patients with the Ser/Gly + Gly/Gly genotype. However, the DRD3 Ser9Gly polymorphism was not associated with changes in other metabolic parameters (Table 2). After correcting for multiple comparisons, the associations between the DRD3 Ser9Gly polymorphism with changes in triglyceride levels become nonsignificant.

View Article: PubMed Central - PubMed

ABSTRACT

Patients with bipolar II disorder (BDII) have a higher prevalence rate of metabolic disturbance. Whether BDII itself, in addition to its current standard treatment, is a risk factor for metabolic syndrome warrants additional study. The dopamine receptor D3 (DRD3) gene, one of the candidate genes for BDII, is also involved in the dopaminergic system. We investigated whether it is related to changes in the metabolic indices of patients with BDII given 12 weeks of standard treatment.

Patients with a first diagnosis of BDII (n = 117) were recruited. Metabolic profiles (cholesterol, triglycerides, fasting serum glucose, body mass index) were measured at baseline and at 2, 8, and 12 weeks. The genotype of the DRD3 Ser9Gly polymorphism (rs6280) was determined. Multiple linear regressions with generalized estimating equation methods were used.

Seventy-six (65.0%) patients completed the 12-week intervention. Significant differences in triglyceride change were associated with the DRD3 Ser9Gly genotype (P = 0.03). Patients with the Ser/Ser genotype had significantly smaller triglyceride increases and a lower risk of developing metabolic syndrome than did those with the Ser/Gly+Gly/Gly genotype. However, the associations between the DRD3 Ser9Gly polymorphism with changes in triglyceride level become nonsignificant after correcting for multiple comparisons.

We conclude that the DRD3 Ser9Gly polymorphism is nominally associated with changes in triglycerides and metabolic syndrome after 12 weeks of standard BDII treatment.

No MeSH data available.


Related in: MedlinePlus